Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

Ovarian cancer is one of the deadliest gynaecological cancers, yet there currently is no early diagnostic test. Here’s what you need to know.

Stage 3 ovarian cancer has spread outside the pelvis into the abdominal cavity or to lymph nodes. Treatment includes surgery and chemotherapy. Stage 3A1 means the cancer has spread to the lymph nodes ...

Anixa Biosciences receives approval of protocol amendment for ovarian cancer CAR-T clinical trial: San Jose, California Friday, February 21, 2025, 18:00 Hrs [IST] Anixa Bioscience ...

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...

This is a significant step in optimizing the treatment for ovarian cancer, and we look forward to continuing our work with Moffitt Cancer Center as we strive to improve outcomes for patients ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...

Feb. 19, 2025 — Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

US and China-based ProfoundBio will use part of the proceeds for a pivotal trial in ovarian cancer of rinatabart sesutecan (Rina-S), a folate receptor-alpha targeted ADC, which is also in ...

Jan. 28, 2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests ... Route of Entry for Semliki ...